JP2020513418A5 - - Google Patents

Download PDF

Info

Publication number
JP2020513418A5
JP2020513418A5 JP2019551494A JP2019551494A JP2020513418A5 JP 2020513418 A5 JP2020513418 A5 JP 2020513418A5 JP 2019551494 A JP2019551494 A JP 2019551494A JP 2019551494 A JP2019551494 A JP 2019551494A JP 2020513418 A5 JP2020513418 A5 JP 2020513418A5
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide
composition according
composition
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019551494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513418A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/064330 external-priority patent/WO2018111580A1/en
Publication of JP2020513418A publication Critical patent/JP2020513418A/ja
Publication of JP2020513418A5 publication Critical patent/JP2020513418A5/ja
Pending legal-status Critical Current

Links

JP2019551494A 2016-12-13 2017-12-01 ウイルス感染を管理するためのポリペプチド Pending JP2020513418A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662433490P 2016-12-13 2016-12-13
US62/433,490 2016-12-13
US201762466066P 2017-03-02 2017-03-02
US62/466,066 2017-03-02
PCT/US2017/064330 WO2018111580A1 (en) 2016-12-13 2017-12-01 Polypeptides for managing viral infections

Publications (2)

Publication Number Publication Date
JP2020513418A JP2020513418A (ja) 2020-05-14
JP2020513418A5 true JP2020513418A5 (enExample) 2021-01-14

Family

ID=62559193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019551494A Pending JP2020513418A (ja) 2016-12-13 2017-12-01 ウイルス感染を管理するためのポリペプチド

Country Status (8)

Country Link
US (2) US10898544B2 (enExample)
EP (2) EP3554533B1 (enExample)
JP (1) JP2020513418A (enExample)
CN (1) CN110325206A (enExample)
AU (1) AU2017377993A1 (enExample)
CA (1) CA3046927A1 (enExample)
MX (1) MX2019006943A (enExample)
WO (1) WO2018111580A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012282678B2 (en) 2011-07-11 2016-03-03 California Institute Of Technology Akt-specific capture agents, compositions, and methods of using and making
US9913875B2 (en) 2015-03-16 2018-03-13 California Institute Of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
WO2017011769A2 (en) 2015-07-15 2017-01-19 California Institute Of Technology Il-17f-specific capture agents, compositions, and methods of using and making
WO2018064597A1 (en) 2016-09-29 2018-04-05 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
EP3554533B1 (en) 2016-12-13 2021-06-09 Emory University Polypeptides for managing viral infections
WO2018232345A1 (en) 2017-06-15 2018-12-20 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
US12201679B2 (en) * 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US598520A (en) 1898-02-08 Marker s record for laundrymen
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
SE9604593D0 (sv) * 1996-12-13 1996-12-13 Sbl Vaccin Ab Antimicrobially active polypeptides
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
CN102448438A (zh) * 2009-03-26 2012-05-09 普马特里克斯公司 抗流行性感冒调配物及方法
EP2755986A4 (en) * 2011-09-12 2015-05-20 Moderna Therapeutics Inc MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR
US9464124B2 (en) * 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20140296137A1 (en) * 2013-04-01 2014-10-02 Los Alamos National Security, Llc Methods and compositions for controlling rotifers
EP3554533B1 (en) 2016-12-13 2021-06-09 Emory University Polypeptides for managing viral infections

Similar Documents

Publication Publication Date Title
JP2020513418A5 (enExample)
JP2015517484A5 (enExample)
RU2020116571A (ru) N4-гидроксицитидин и производные и связанные с этим противовирусные применения
JP2015078230A5 (enExample)
PH12017502326A1 (en) Orodispersible dosage unit containing an estetrol component
FI3430027T3 (fi) Peptidi käytettäväksi ei-pienisoluisen keuhkosyövän ja pienisoluisen keuhkosyövän hoidossa
WO2019043634A3 (en) CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
RU2019105294A (ru) Композиции и способы для модуляции передачи сигнала lair
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
JP2015529685A5 (enExample)
US20080118556A1 (en) Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
JP2015510393A5 (enExample)
RU2018140900A (ru) Семаглутид при сердечно-сосудистых состояниях
RU2018142174A (ru) Контролируемая пищевым рационом экспрессия нуклеиновой кислоты, кодирующей нуклеазу cas9, и ее применения
RU2019113989A (ru) Лекарственное средство
JP2019500379A5 (enExample)
WO2019078663A3 (ko) 아연염, 시클로-히스프로 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
HRP20241042T1 (hr) Novi analozi inzulina i njihova upotreba
JP2019505210A5 (enExample)
RU2015113031A (ru) Использование 3-n-бутил изоиндолин кетонов при приготовлении лекарственных средств для профилактики и лечения церебрального инфаркта
JP2017007966A5 (enExample)
JP2014512353A5 (enExample)
JP2017008001A5 (enExample)
WO2018108939A3 (de) Feste pharmazeutische orale darreichungsform mit verlängerter wirkstofffreisetzung umfassend mirabegron
MX2019013874A (es) Peptidos y sus usos como agentes antivirales.